Related Experiment Video

Updated: Jun 22, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer

David O Azorsa1, Irma M Gonzales, Gargi D Basu

  • 1Pharmaceutical Genomics Division, The Translational Genomics Research Institute, Scottsdale, Arizona 85259, USA. dazorsa@tgen.org

Journal of Translational Medicine
|June 13, 2009
PubMed
Abstract

Insights

Checkpoint kinase 1 (CHK1) inhibition sensitizes pancreatic cancer cells to gemcitabine. This synthetic lethal screen identified CHK1 as a potential therapeutic target to improve pancreatic cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic cancer has a poor prognosis and limited treatment options.
  • Gemcitabine is a standard chemotherapy with challenges in efficacy and resistance.
  • Current combination therapies offer minimal improvement.

Purpose of the Study:

  • To identify novel therapeutic targets for sensitizing pancreatic cancer cells to gemcitabine.
  • To explore synthetic lethality approaches for overcoming gemcitabine resistance.

Main Methods:

  • Conducted a large-scale synthetic lethal RNAi screen targeting 572 kinases.
  • Utilized small interfering RNA (siRNA) to silence specific genes in pancreatic cancer cells.
  • Validated findings using dose-response assays and small molecule inhibitors.

Main Results:

  • Silencing of several kinases potentiated gemcitabine's growth inhibitory effects.
  • Checkpoint kinase 1 (CHK1) silencing demonstrated the greatest potentiation.
  • CHK1 inhibition significantly decreased the EC50 of gemcitabine in pancreatic cancer cells.

Conclusions:

  • Synthetic lethal RNAi screening is effective for identifying drug sensitizing targets.
  • CHK1 is a promising therapeutic target for enhancing gemcitabine efficacy in pancreatic cancer.
  • Targeting CHK1 may offer a new strategy to improve pancreatic cancer treatment.

More Related Videos

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...